ArticleAntibiotics (Basel, Switzerland)2014
Anti-Biofilm and Immunomodulatory Activities of Peptides That Inhibit Biofilms Formed by Pathogens Isolated from Cystic Fibrosis Patients.
Article in Antibiotics (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Article
- Synthetic peptides targeting a mast cell-specific G protein-coupled receptor MRGPRB2 display anti-infective potential.Cell biomaterials · 2025Article
- Enhanced bacteriostatic effects of phage vB_C4 and cell wall-targeting antibiotic combinations against drug-resistantMicrobiology spectrum · 2025Article
- Biofilm inhibition/eradication: exploring strategies and confronting challenges in combatting biofilm.Archives of microbiology · 2024Review
- Antibiotic Resistant Biofilms and the Quest for Novel Therapeutic Strategies.Indian journal of microbiology · 2024Review
- Anti-Virulence Potential of a Chionodracine-Derived Peptide against Multidrug-ResistantInternational journal of molecular sciences · 2022Article
- BosR: A novel biofilm-specific regulator inFrontiers in microbiology · 2022Article
- D1018 with higher stability and excellent lipopolysaccharide binding affinity has potent anti-bacterial and anti-inflammatory activity.Frontiers in microbiology · 2022Article
- Identification of the Active Principle Conferring Anti-Inflammatory and Antinociceptive Properties in Bamboo Plant.Molecules (Basel, Switzerland) · 2021Article
- Molecular Dynamics for Antimicrobial Peptide Discovery.Infection and immunity · 2021Review
- Review
- Bacteriophage-Derived Depolymerases against Bacterial Biofilm.Antibiotics (Basel, Switzerland) · 2021Review
- Alternative Approaches for the Management of Diabetic Foot Ulcers.Frontiers in microbiology · 2021Review
- Phenotypical Characteristics of the Black YeastFrontiers in microbiology · 2020Article
- Antibacterial activity of aVirulence · 2019Article
- Peptide and non-peptide mimetics as potential therapeutics targeting oral bacteria and oral biofilms.Molecular oral microbiology · 2019Review
- Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.Scientific reports · 2019Article
- Reassessing the Host Defense Peptide Landscape.Frontiers in chemistry · 2019Review
- Article
- Inhibition and Eradication of Pseudomonas aeruginosa Biofilms by Host Defence Peptides.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Cystic fibrosis (CF) patients often acquire chronic respiratory tract infections due to Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc) species. In the CF lung, these bacteria grow as multicellular aggregates termed biofilms. Biofilms demonstrate increased (adaptive) resistance to conventional antibiotics, and there are currently no available biofilm-specific therapies. Using plastic adherent, hydroxyapatite and flow cell biofilm models coupled with confocal and scanning electron microscopy, it was demonstrated that an anti-biofilm peptide 1018 prevented biofilm formation, eradicated mature biofilms and killed biofilms formed by a wide range of P. aeruginosa and B. cenocepacia clinical isolates. New peptide derivatives were designed that, compared to their parent peptide 1018, showed similar or decreased anti-biofilm activity against P. aeruginosa biofilms, but increased activity against biofilms formed by the Gram-positive bacterium methicillin resistant Staphylococcus aureus. In addition, some of these new peptide derivatives retained the immunomodulatory activity of 1018 since they induced the production of the chemokine monocyte chemotactic protein-1 (MCP-1) and suppressed lipopolysaccharide-mediated tumor necrosis factor-α (TNF-α) production by human peripheral blood mononuclear cells (PBMC) and were non-toxic towards these cells. Peptide 1018 and its derivatives provide promising leads for the treatment of chronic biofilm infections and hyperinflammatory lung disease in CF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.